NCT07122167招募中不适用
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesion
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- MDCECRO LLC
- 入组人数
- 153
- 试验地点
- 2
- 主要终点
- Primary patency at 12 months post-procedure
研究概览
简要总结
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be followed at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Aged 18 to 80 years, regardless of gender. (2) Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or
- •(3) Subject (or legal guardian, if applicable) is willing and able to provide consent before to the performance of any study specific tests or procedures, has signed the consent form and agrees to attend all required follow-up visits.
- •Angiographic Inclusion Criteria:
- •Eligible subjects must meet all of the following angiographic criteria:
- •Stenotic, restenotic or occlusive lesion(s) located in the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) (i.e., within the P1 segment):
- •Degree of stenosis ≥70% by visual angiographic assessment.
- •Vessel diameter ≥4.0 mm and ≤6.5 mm.
- •Total lesion length (or series of lesions) ≥ 10 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one stent).
- •Chronic total occlusion with a total lesion length of ≤120 mm.
- •Patent popliteal and infrapopliteal arteries, with single-vessel runoff or better, defined as at least one of the three vessels remaining patent (i.e., <50% stenosis) down to the ankle or foot.
排除标准
- •Clinical exclusion criteria:
- •Subjects will be excluded from the study if any of the following conditions are present:
- •Pregnant or breastfeeding women, or women/men planning to conceive.
- •Subjects who have had or are planned for major amputation (at or above the ankle level).
- •Subjects known to be allergic or intolerant to materials used in the investigational device or treatment drugs, including nitinol, paclitaxel, aspirin, clopidogrel, heparin, rivaroxaban, contrast agents, etc.
- •Subjects with serum creatinine ≥2.5 mg/dL or currently undergoing dialysis.
- •Subjects with known, uncorrectable hemorrhagic disorders or severe coagulation dysfunction (prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≥2 times the upper limit of normal, or platelet count <80×10⁹/L).
- •Previously stented target lesion/vessel.
- •Target lesion/vessel previously treated with drug-coated balloon <12 months prior to enrollment.
- •Subjects with a life expectancy of less than 1 year.
- •Subjects who have received local or systemic thrombolysis treatment within 48 hours prior to enrollment.
- •Subjects diagnosed with major clinical diseases or unstable conditions within the past 3 months, such as severe heart failure, unstable angina, myocardial infarction, transient ischemic attack or stroke, severe neurological or psychiatric history, severe infections, gastrointestinal bleeding, or active disseminated intravascular coagulation.
- •Subjects currently participating in another clinical trial involving drugs or medical devices.
- •Subjects whom the investigator considers unsuitable for participation in the clinical trial.
- •Angiographic exclusion criteria:
- •Presence of aneurysm in the target vessel.
- •Heavily calcified lesions (Peripheral Arterial Calcium Scoring System [PACSS] grades 3-4).
- •The target lesion requires the use of plaque excision, laser, or other debulking devices that may damage the vessel intima.
- •The guidewire cannot pass through the target lesion, or percutaneous transluminal angioplasty (PTA) balloon cannot be used for pre-dilation.
- •Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment.
结局指标
主要结局
Primary patency at 12 months post-procedure
时间窗: 12 Months
Primary vessel patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤2.4 at the 12-month follow-up visit in the absence of clinically driven TLR or bypass of the target lesion.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
MANTA Registry for Vascular Large-bore ClosureFemoral Arteriotomy ClosureNCT03330002Essential Medical, Inc.500
已完成
不适用
Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion StentCoronary ArteriosclerosisNCT00968019Johnson and Johnson, S.A.318
已完成
不适用
MDR EZ Pass and Precision Flexible ReamerRotator Cuff TearAnterior Cruciate Ligament InjuryNCT03914703Zimmer Biomet73
已完成
不适用
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz StentCoronary Artery DiseaseNCT04138238Sahajanand Medical Technologies Limited1,200
已完成
不适用
Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery DiseaseSuperficial Femoral Artery DiseasePopliteal Artery DiseaseNCT04546477Terumo Europe N.V.135